The current report offers a detailed picture of the market for COVID-19 diagnostics.
COVID-19 is an infectious disease that is caused by the coronavirus and primarily affects the lungs.

This report highlights the current and future market potential for COVID-19 diagnostics and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2027, as well as market shares for key market players.

This report details market shares for COVID-19 diagnostics based on type, technology, end-user and geography. Based on type, the market is segmented into molecular tests and serology tests segments. Based on technology, the market is segmented into reverse transcription polymerase chain reaction (RT-PCR), isothermal amplification, clustered regularly interspaced short palindromic repeats (CRISPR), enzyme-linked immunosorbent assay (ELISA), hybridization and others.

By geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are covered in regional segments. For market estimates, data has been provided for 2020 as the base year, with forecasts for 2021 through 2027. Estimated values are based on diagnostics manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.